## AMENDMENTS TO THE CLAIMS

Docket No.: 21059/0206916-US0

Please replace the claims, including all prior versions, with the listing of claims below.

## **LISTING OF CLAIMS:**

- 1-21 (Cancelled)
- 22. (Previously Presented) A method of treating, managing or preventing obstructive lung disease comprising:

administering to a patient a pharmaceutical composition comprising an effective amount of (a) Mycobacterium w or (b) a constituent of Mycobacterium w.

23. (Currently amended) The method of claim 22A method of treating, managing or preventing obstructive lung disease comprising:

administering to a patient a pharmaceutical composition comprising an effective amount of (a) Mycobacterium w or (b) a constituent of Mycobacterium w, wherein the method is for treating, managing or preventing asthma.

- 24. (Previously Presented) The method of 23, wherein the method is for delaying attacks of asthma.
- 25. (Previously Presented) The method of 23, wherein the method is for reducing the requirement of drugs used to improve lung function during the management of asthma.
- 26. (Previously Presented) The method of claim 23, wherein the method is for improving lung function in the presence or absence of other drugs.
- 27. (Previously Presented) The method of claim 23, wherein the asthma is bronchial asthma.

Application No. 10/565,211 Amendment dated July 8, 2008 Reply to Office Action of April 8, 2008

Docket No.: 21059/0206916-US0

- 28. (Previously Presented) The method of claim 22, wherein the pharmaceutical composition comprises an admixture of Mycobacterium w and constituents of mycobacterium w prepared by cell disruption.
- 29. (Previously Presented) The method of claim 22, wherein the pharmaceutical composition comprises constituents of Mycobacterium w prepared by cell disruption.
- 30. (Previously Presented) The method of claim 28, wherein the constituents of Mycobacterium w are prepared by sonication or high pressure fractionometer.
- 31. (Previously Presented) The method of claim 29, wherein the constituents of Mycobacterium w are prepared by sonication or high pressure fractionometer.
- 32. (Previously Presented) The method of claim 22, wherein the pharmaceutical composition comprises constituents of Mycobacterium w prepared by solvent extraction.
- 33. (Previously Presented) The method of claim 32, wherein the solvent is selected from the group consisting of chloroform, ethanol, methanol, acetone, phenol, isopropyl alcohol, acetic acid, urea and hexane.
- 34. (Previously Presented) The method of claim 22, wherein the pharmaceutical composition comprises constituents of Mycobacterium w prepared by enzymatic extraction.

Application No. 10/565,211
Amendment dated July 8, 2008
Parkers Office Assistance of April 8, 2008

Reply to Office Action of April 8, 2008

35. (Previously Presented) The method of claim 34, wherein the enzymatic extraction is carried out using lyticase and/or pronase.

- 36. (Previously Presented) The method of claim 22, wherein the pharmaceutical composition further comprises an adjuvant.
- 37. (Previously Presented) The method of claim 36, wherein the adjuvant is selected from mineral oil, mineral oil and surfactant, Ribi adjuvant, Titermax, syntax adjuvant formulation, aluminum salt adjuvant, nitrocellulose adsorbed antigen, immune stimulating complexes, Gebru adjuvant, super carrier, elvax 40w, L-tyrosine, monatanide (manide oleate compound), Adju prime, Squalene, Sodium phthalyl lipopoly saccharide, calcium phosphate, saponin, melanoma antigen and muramyl dipeptide (MDP).
- 38. (Previously Presented) The method of claim 22, wherein the pharmaceutical composition further comprises a surfactant.
- 39. (Previously Presented) The method of claim 38, wherein the surfactant is polyoxyethylene sorbitan monooleate (Tween 80) or Triton X100.
- 40. (Previously Presented) The method of claim 38, wherein the surfactant is present in the pharmaceutical composition in a concentration of up to 0.4%.
- 41. (Previously Presented) The method of claim 38, wherein the surfactant is present in the pharmaceutical composition in a concentration of up to 0.1%.

Docket No.: 21059/0206916-US0

Application No. 10/565,211 Amendment dated July 8, 2008 Reply to Office Action of April 8, 2008

- 42. (Previously Presented) The method of claim 22, wherein the pharmaceutical composition further comprises a preservative.
- 43. (Previously Presented) The method of claim 42, wherein the preservative is Thiomerosal and is present in a concentration of 0.01% w/v.
- 44. (Previously Presented) The method of claim 22, wherein the Mycobacterium w is dead mycobacterium w.
- 45. (Previously Presented) The method of claim 22, wherein the pharmaceutical composition is in a unit dosage form comprising at least 10<sup>5</sup> Mycobacterium w.
- 46. (Previously Presented) The method of claim 22, wherein the pharmaceutical composition is in a unit dosage form comprising at least 10<sup>7</sup> Mycobacterium w.
- 47. (Previously Presented) The method of claim 22, wherein the pharmaceutical composition is in a unit dosage form comprising between  $10^8$  and  $10^9$  Mycobacterium w.
- 48. (Currently amended) The method of claim 22A method of treating, managing or preventing obstructive lung disease comprising:

administering to a patient a pharmaceutical composition comprising an effective amount of (a) Mycobacterium w or (b) a constituent of Mycobacterium, wherein the constituent of Mycobacterium w is prepared by cell disruption, solvent extraction, or enzymatic extraction.

Docket No.: 21059/0206916-US0